Direxion mRNA ETF (MSGR) Stock Analysis
DELISTED 2023
What happened to Direxion mRNA ETF (MSGR) stock?
Direxion mRNA ETF (MSGR) no longer trades on public markets. It was delisted in April 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Direxion mRNA ETF (MSGR) trades at $13.91. Direxion mRNA ETF (MSGR) aims to track the performance of companies leading the development and application of messenger RNA (mRNA) technology. Sector: Financial services.
Last analyzed: Mar 17, 2026Analyst Coverage for MSGR: MSGR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MSGR against Financial Services peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Direxion mRNA ETF (MSGR) Financial Services Profile
Direxion mRNA ETF (MSGR) offers targeted exposure to companies at the forefront of messenger RNA (mRNA) technology, primarily in the US, Canada, and Europe. As a non-diversified fund, MSGR provides investors with a focused approach to capitalize on the growth potential within the rapidly evolving biotechnology sector, specifically mRNA advancements.
What Is the Investment Thesis for MSGR?
The Direxion mRNA ETF (MSGR) presents a focused investment opportunity within the rapidly advancing field of mRNA technology. The fund's value is intrinsically linked to the success and growth of companies pioneering mRNA applications in vaccines, therapeutics, and diagnostics. Key value drivers include the clinical trial outcomes, regulatory approvals, and commercialization success of mRNA-based products. Ongoing catalysts include the expansion of mRNA technology into new therapeutic areas and the increasing adoption of mRNA vaccines. Potential risks include clinical trial failures, regulatory hurdles, and competition from alternative technologies. Investors should monitor the performance of key holdings within the fund and assess the overall market sentiment towards mRNA technology to evaluate the potential returns and risks associated with MSGR.
Based on FMP financials and quantitative analysis
MSGR Key Highlights
MSGR provides targeted exposure to the mRNA technology sector.
- The fund invests at least 80% of its assets in securities comprising the underlying index.
- MSGR focuses on companies publicly listed in the United States, Canada, and Europe.
- As a non-diversified fund, MSGR's performance is closely tied to a concentrated group of companies.
- MSGR offers investors the flexibility to buy and sell shares throughout the trading day.
Who Are MSGR's Competitors?
MSGR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IBB iShares Biotechnology ETF | $210.83 | -2.83% | $10.4B | 47 |
| XBI State Street SPDR S&P Biotech ETF | $163.79 | -3.40% | $8.56B | 47 |
| ABALX American Funds American Balanced Fund Class A | $41.00 | +0.37% | $292B | 72 |
| BX Blackstone Inc. | $141.41 | -2.54% | $171B | 81 |
| AMFCX American Funds American Mutual Fund | $63.80 | -0.72% | $77.4B | 71 |
| RNNEX American Funds The New Economy Fund Class R-2E | $80.46 | -0.29% | $52.9B | 91 |
| AMP Ameriprise Financial, Inc. | $554.06 | -1.02% | $49.8B | 70 |
| IDDTF AB Industrivärden (publ) | $54.65 | -0.36% | $23.6B | 70 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MSGR's Key Strengths?
Focused exposure to the high-growth mRNA technology sector.
- Transparent and rules-based investment approach.
- Access to a diversified portfolio of mRNA companies.
- Potential for high returns due to the growth potential of mRNA technology.
What Are MSGR's Weaknesses?
Non-diversified structure increases risk.
- Performance is highly dependent on the success of mRNA technology.
- Vulnerable to regulatory changes and clinical trial failures.
- Management fees can impact overall returns.
What Could Drive MSGR Stock Higher?
Clinical trial results for mRNA-based therapies.
- Regulatory approvals for new mRNA vaccines.
- Expansion of mRNA technology into new therapeutic areas.
- Increasing adoption of mRNA vaccines.
What Are the Key Risks for MSGR?
Clinical trial failures.
- Regulatory hurdles.
- Competition from alternative technologies.
- Market volatility and economic downturns.
- Dependence on the success of a relatively small number of companies.
What Are the Growth Opportunities for MSGR?
- Expansion into New Therapeutic Areas: mRNA technology is being explored for its potential in treating a wide range of diseases, including cancer, infectious diseases, and genetic disorders. As mRNA-based therapies advance through clinical trials and receive regulatory approvals, the market size for mRNA therapeutics is expected to grow significantly. This expansion presents a growth opportunity for MSGR, as the fund's holdings could benefit from the increased adoption of mRNA technology in new therapeutic areas. The timeline for this growth is dependent on the success of ongoing clinical trials and the regulatory approval process.
- Increasing Adoption of mRNA Vaccines: The success of mRNA vaccines in combating infectious diseases has demonstrated the potential of mRNA technology in preventing and treating diseases. As new mRNA vaccines are developed and approved, the market for mRNA vaccines is expected to continue to grow. This growth presents a growth opportunity for MSGR, as the fund's holdings could benefit from the increased adoption of mRNA vaccines. The timeline for this growth is dependent on the development and approval of new mRNA vaccines.
- Advancements in mRNA Delivery Technologies: The effectiveness of mRNA therapeutics and vaccines depends on the ability to deliver mRNA molecules to the target cells. Advancements in mRNA delivery technologies, such as lipid nanoparticles, are improving the efficiency and safety of mRNA delivery. These advancements present a growth opportunity for MSGR, as the fund's holdings could benefit from the development and adoption of improved mRNA delivery technologies. The timeline for this growth is dependent on the progress of research and development in mRNA delivery technologies.
- Strategic Partnerships and Collaborations: Companies in the mRNA technology space are increasingly forming strategic partnerships and collaborations to accelerate the development and commercialization of mRNA-based products. These partnerships can provide access to new technologies, expertise, and funding, which can drive growth and innovation. MSGR's holdings could benefit from these partnerships, as they can lead to the development of new and improved mRNA products. The timeline for this growth is dependent on the formation and success of these partnerships.
- Increased Investment in mRNA Research and Development: Governments, academic institutions, and private companies are investing heavily in mRNA research and development. This increased investment is driving innovation and accelerating the development of new mRNA technologies. MSGR's holdings could benefit from this increased investment, as it can lead to the discovery of new mRNA applications and the development of improved mRNA products. The timeline for this growth is dependent on the continued investment in mRNA research and development.
What Are MSGR's Competitive Advantages?
- Focused exposure to a specific and rapidly growing technology (mRNA).
- Transparent and rules-based investment approach.
- Access to a diversified portfolio of mRNA companies.
What Does MSGR Do?
Direxion mRNA ETF (MSGR) is designed to provide investors with exposure to companies that are leading the development and application of messenger RNA (mRNA) technology. This exchange-traded fund operates by investing at least 80% of its assets in securities that comprise its underlying index or in investments that exhibit similar economic characteristics. The fund's investment scope includes companies publicly listed in the United States, Canada, and Europe, reflecting a global perspective on mRNA innovation. The ETF's focus on mRNA technology places it within the broader biotechnology and pharmaceutical industries, where mRNA is being explored for its potential in vaccines, therapeutics, and diagnostics. MSGR's non-diversified structure means that its performance is closely tied to the success of a relatively concentrated group of companies, making it a potentially higher-risk, higher-reward investment option. The fund's objective is to mirror the performance of its underlying index, providing a transparent and rules-based approach to investing in the mRNA space. As an ETF, MSGR offers investors the flexibility to buy and sell shares throughout the trading day, similar to individual stocks.
What Products and Services Does MSGR Offer?
- Invests in companies developing messenger RNA (mRNA) technology.
- Tracks the performance of an index focused on mRNA companies.
- Provides exposure to companies publicly listed in the US, Canada, and Europe.
- Operates as a non-diversified fund.
- Offers investors a way to invest in the mRNA technology space.
- Seeks to mirror the performance of its underlying index.
How Does MSGR Make Money?
- Generates revenue through management fees charged to investors.
- Invests in securities that comprise its underlying index.
- Provides a rules-based approach to investing in the mRNA space.
What Industry Does MSGR Operate In?
Direxion mRNA ETF (MSGR) operates within the asset management industry, specifically targeting the biotechnology sector with a focus on messenger RNA (mRNA) technology. The mRNA market is experiencing rapid growth, driven by the success of mRNA vaccines and the potential for mRNA therapeutics in various diseases. The competitive landscape includes other biotechnology ETFs and mutual funds, as well as individual companies developing mRNA technologies. MSGR differentiates itself by providing a focused approach to investing in mRNA companies, offering investors a way to capitalize on the growth potential of this specific area within the biotechnology industry.
Who Are MSGR's Key Customers?
- Institutional investors seeking exposure to mRNA technology.
- Retail investors interested in the biotechnology sector.
- Financial advisors looking for targeted investment opportunities.
Key Financial Metrics
Return on equity for Direxion mRNA ETF stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. MSGR trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.
MSGR Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the mRNA sector's long-term growth potential, indicating that key stakeholders believe in the future of this technology.
- Community sentiment has shifted positively, with discussions highlighting the increasing relevance of mRNA in vaccine development and therapeutics.
- Market perception is buoyed by recent advancements in mRNA research, which could lead to new partnerships and innovations within the ETF's holdings.
- The overall trend in biotech investments is leaning bullish, as investors are increasingly recognizing the value of mRNA technologies post-pandemic.
Bear Case
- Some community members express concerns over the volatility associated with biotech ETFs, leading to hesitation in investment decisions.
- Recent news of regulatory scrutiny in the biotech sector has created uncertainty, causing some investors to adopt a more cautious stance.
- The market sentiment is mixed due to ongoing debates about the sustainability of mRNA technology's growth, with critics questioning its long-term viability.
- Insider selling activity has raised red flags for some, suggesting that certain stakeholders may be looking to capitalize on current market highs rather than hold for the long term.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MSGR Latest News
No recent news available for MSGR.
Direxion mRNA ETF Financial Services Stock: Key Questions Answered
What happened to Direxion mRNA ETF (MSGR) stock?
Direxion mRNA ETF (MSGR) no longer trades on public markets. It was delisted in April 2023. The figures below are historical and are not a current quote.
Can I still buy MSGR shares?
No. MSGR stopped trading on public markets in April 2023, so the shares are not available through a broker. Anything you see quoted for MSGR elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before MSGR stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Direxion mRNA ETF. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Direxion mRNA ETF do?
Direxion mRNA ETF (MSGR) is designed to track the performance of companies that are leading the development and application of messenger RNA (mRNA) technology. The fund invests primarily in publicly listed companies in the United States, Canada, and Europe, providing investors with targeted exposure to the mRNA space.
What are the main risks for MSGR?
The Direxion mRNA ETF (MSGR) is subject to several risks, including clinical trial failures, regulatory hurdles, and competition from alternative technologies. Clinical trial failures can negatively impact the stock prices of companies developing mRNA-based therapies, which can in turn affect the fund's performance.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on available data and is subject to change.
- Investment decisions should be made based on individual risk tolerance and financial goals.